Corey Michael Watton net worth and biography

Corey Watton Biography and Net Worth

Director of Zevra Therapeutics

Corey Watton has served as a director of our Company since April 2023. Mr. Watton currently serves as president and chief executive officer of Fusion Medical Staffing, LLC, since September 2023. Prior to his CEO role, Mr. Watton served as chief financial officer from August 2019 until September 2023. In that role he oversaw finance, project management, operations, facilities and legal, and previously oversaw human resources as well. From April 2009 through July 2019, he served as the chief financial officer of Home Instead Senior Health Care, a global leader in in-home health care, where he oversaw finance, subsidiary companies and the financial arm of an international subsidiary. He previously was a partner of Lutz & Company, a regional accounting firm from 1996 to 2009. Mr. Watton is a certified public accountant and received a BS in Finance and Accounting from University of Nebraska-Lincoln.

What is Corey Michael Watton's net worth?: The estimated net worth of Corey Michael Watton is at least $15.59 thousand as of March 28th, 2025. Mr. Watton owns 1,800 shares of Zevra Therapeutics stock worth more than $15,588 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Watton may own. Learn More about Corey Michael Watton's net worth.
How do I contact Corey Michael Watton?: The corporate mailing address for Mr. Watton and other Zevra Therapeutics executives is 1180 Celebration Boulevard Suite 103, Celebration FL, 34747. Zevra Therapeutics can also be reached via phone at (321) 939-3416 and via email at [email protected]. Learn More on Corey Michael Watton's contact information.
Has Corey Michael Watton been buying or selling shares of Zevra Therapeutics?: Corey Michael Watton has not been actively trading shares of Zevra Therapeutics during the last quarter. Most recently, on Friday, March 28th, Corey Michael Watton bought 300 shares of Zevra Therapeutics stock. The stock was acquired at an average cost of $7.84 per share, with a total value of $2,352.00. Following the completion of the transaction, the director now directly owns 1,800 shares of the company's stock, valued at $14,112. Learn More on Corey Michael Watton's trading history.
Who are Zevra Therapeutics' active insiders?: Zevra Therapeutics' insider roster includes Thomas Anderson (Director), John Bode (Director), R. Clifton (Chief Financial Officer & Treasurer), Neil McFarlane (President & Chief Executive Officer), Timothy Sangiovanni (Senior Vice President, Corporate Controller), Joshua Schafer (Chief Commercial Officer), and Corey Watton (Director). Learn More on Zevra Therapeutics' active insiders.
Are insiders buying or selling shares of Zevra Therapeutics?: In the last year, Zevra Therapeutics insiders bought shares 4 times. They purchased a total of 18,475 shares worth more than $152,485.25. In the last year, insiders at the sold shares 5 times. They sold a total of 105,273 shares worth more than $885,165.78. The most recent insider tranaction occured on October, 10th when CEO Neil F Mcfarlane sold 19,500 shares worth more than $210,990.00. Insiders at Zevra Therapeutics own 2.4% of the company. Learn More about insider trades at Zevra Therapeutics.
Information on this page was last updated on 10/10/2025.

Corey Michael Watton Insider Trading History at Zevra Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/28/2025	Buy	300	$7.84	$2,352.00	1,800
10/11/2024	Buy	500	$7.92	$3,960.00	1,500
6/23/2023	Buy	275	$5.95	$1,636.25	1,000
6/9/2023	Buy	325	$5.52	$1,794.00	725
5/30/2023	Buy	400	$5.11	$2,044.00	400

Corey Michael Watton Buying and Selling Activity at Zevra Therapeutics

Zevra Therapeutics Company Overview

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Today's Range

Now: $8.66

$8.48

$8.80

50 Day Range

MA: $9.79

$8.17

$11.78

2 Week Range

Now: $8.66

$6.19

$13.16

Volume

823,188 shs

Average Volume

1,395,027 shs

Market Capitalization

$487.56 million

P/E Ratio

18.43

Dividend Yield

N/A

Beta

1.01